Technology transfer / Localization · GCC · Announced 30 Jul 2025
BioGeneric Pharma → GWM
Egypt's BioGeneric Pharma and Saudi Arabia's GWM signed a strategic partnership to localize vaccine and biologics manufacturing in the Kingdom through technology transfer and a new facility.
Parties: BioGeneric Pharma (Egypt) → GWM (Saudi Arabia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia
- Therapeutic area
- Vaccines
- Asset
- Vaccines and biologics (products not named)
- Announced
- 30 Jul 2025
Our analysis
Why this matters
BioGeneric Pharma, an Egyptian biotech company, and GWM, described as a Saudi company, signed a strategic partnership, reported on 30 July 2025, to localize vaccine and biologics manufacturing in Saudi Arabia. The partnership rests on three pillars: transfer of regulated vaccine-production technology from Egypt to Saudi Arabia through a new, modern facility; direct operational entry for BioGeneric into the Saudi market; and local manufacturing under licensing or joint-venture models. Value, site, timelines and products were not disclosed.
It is a south-to-south transfer: an Egyptian biotech exporting manufacturing know-how to the Gulf, not a Western multinational. For BD directors, Egyptian biologics players are emerging as technology partners for Saudi localization, not only as suppliers.
The full analysis is free to read with a work email on this page.
Source: Dawaa News MENA